Mode
Text Size
Log in / Sign up
Phase 1 Completed N=20 Randomized Single-blind Basic Science

Assessing the PK of Met DR, Met IR, and Met XR in Healthy Subjects

Healthy Subjects
Source: ClinicalTrials.gov NCT02291510 ↗
Enrolled (actual)
20
Serious AEs
0.0%
Results posted
Sep 2015
Primary outcomePrimary: AUC (0-t) of Plasma Metformin — 6164; 9014; 18709; 16989 ng*h/mL — p=<0.001

Summary

This study compared the pharmacokinetics (PK) and assessed the safety of delayed-release metformin (Met DR, EFB0027) at two dosage levels, immediate-release metformin (Met IR, ETB0015), and extended-release metformin (Met XR, ETB0014) in healthy subjects.

Outcome Measures

OutcomeResultp-value
PRIMARY
AUC (0-t) of Plasma Metformin
6164; 9014; 18709; 16989 <0.001 sig
PRIMARY
Cmax of Plasma Metformin
607; 905; 1328; 1688 <0.001 sig

Eligibility Criteria

Inclusion Criteria

  • 19 to 65 (inclusive) years old at Visit 1 (Screening)
  • Male, or if female and met all of the following criteria:
  • Not breastfeeding
  • Negative pregnancy test result at Visit 1 (Screening) (not applicable to hysterectomized females)
  • Surgically sterile, postmenopausal, or if of childbearing potential, practiced and was willing to continue to practice appropriate birth control during the entire duration of the study
  • Body mass index (BMI) of 25.0 to 35.0 kg/m² (inclusive) at Visit 1 (Screening)
  • Had a physical examination with no clinically significant abnormalities as judged by the investigator
  • Had normal renal function with an estimated glomerular filtration rate (eGFR) ≥90 mL/min/1.73 m² based on the Modification of Diet in Renal Disease (MDRD) equation
  • Ability to understand and willingness to adhere to protocol requirements

Exclusion Criteria

  • Had a clinically significant medical condition as judged by the investigator that could potentially affect study participation and/or personal well-being, including but not limited to the following conditions:
  • Hepatic disease
  • Gastrointestinal disease
  • Endocrine disorder (including diabetes and impaired glucose tolerance)
  • Cardiovascular disease
  • Central nervous system diseases
  • Psychiatric or neurological disorders
  • Organ transplantation
  • Chronic or acute infection
  • Orthostatic hypotension, fainting spells or blackouts
  • Allergy or hypersensitivity
  • Had any chronic disease requiring medication that was adjusted in the past 90 days (subjects could take acute intermittent over-the-counter medications such as Tylenol, if needed)
  • Had major surgery of any kind within 6 months of Visit 1 (Screening)
  • Had a history of >6 kg weight change within 3 months of Visit 1 (Screening)
  • Had clinical laboratory test (clinical chemistry, hematology, or urinalysis) abnormalities judged by the investigator to be clinically significant at Visit 1 (Screening)
  • Had a physical, psychological, or historical finding that, in the investigator's opinion, would make the subject unsuitable for the study
  • Had any drug treatment that affects gastric pH (prescription or over-the-counter), including any antacids or medications such as Rolaids or Pepcid within 2 days of Visit 1 (Screening)
  • Currently abused drugs or alcohol or had a history of abuse that in the investigator's opinion would cause the individual to be noncompliant with study procedures
  • Smoked more than 10 cigarettes per day, 3 cigars per day, 3 pipes per day, used more than 1 can of smokeless tobacco per week, or used a combination of tobacco products that approximate nicotine doses equivalent to 10 cigarettes per day
  • Had donated blood within 3 months of the date of the first dose of randomized study medication, or was planning to donate blood during the study
  • Had received any investigational drug within 2 months (or five half-lives of the investigational drug, whichever was greater) of the date of the first dose of randomized study medication
  • Had known allergies or hypersensitivity to any component of study treatment
  • Was employed by Elcelyx Therapeutics, Inc (that is an employee, temporary contract worker, or designee of the company)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02291510). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search